Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy: The role of CYP3A and P-glycoprotein

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 3, 2006, Pages 1202-1209

  Mathias, Anita A ^a   Maggio Price, Lillian ^a   Lai, Yurong ^a   Gupta, Anshul ^a   Unadkat, Jashvant D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A4; GLYCOPROTEIN P; NELFINAVIR; PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; ENZYME ACTIVITY; FEMALE; GESTATIONAL AGE; HYDROXYLATION; INTESTINE; LIVER; METABOLISM; MOUSE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PLASMA CLEARANCE; PREGNANCY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANIMALS; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; FEMALE; HIV PROTEASE INHIBITORS; MICE; NELFINAVIR; P-GLYCOPROTEIN; PREGNANCY; PREGNANCY, ANIMAL;

EID: 33644745294     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.095406     Document Type: Article

References (38)

1. Acosta EP (2002) Pharmacokinetic enhancement of protease inhibitors. J Acquir Immune Defic Syndr 29 (Suppl 1):S11-S18.
2. Acosta EP, Zorrilla C, Van Dyke R, Bardeguez A, Smith E, Hughes M, Huang S, Pitt J, Watts H, and Mofenson L (2001) Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials 2:460-465.
3. Anderson PL, Brundage RC, Bushman L, Kakuda TN, Remmel RP, and Fletcher CV (2000) Indinavir plasma protein binding in HIV-1-infected adults. AIDS 14:2293-2297.
4. Angel JB, Khaliq Y, Monpetit ML, Cameron DW, and Gallicano K (2001) An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy. AIDS 15:417-419.
5. Bryson YJ, Stek A, Mirochnick M, Mofenson L, Connor J, Watts H, Huang S, Hughes M, Cunningham B, Purdue L, et al. (2002) Pharmacokinetics, antiviral activity and safety of nelfinavir (NFV) with ZDV/3TC in pregnant HIV-infected women and their infants: PACTG 353 Cohort 2, in 9th Annual Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle, WA. Abstract 795-W, The Foundation for Retrovirology and Human Health, Alexandria, VA; The National Institute of Allergy and Infectious Diseases, Rockville, MD; and The Centers for Disease Control and Prevention, Atlanta, GA.
6. Dai D, Bai R, Hodgson E, and Rose RL (2001) Cloning, sequencing, heterologous expression and characterization of murine cytochrome P450 3a25*(Cyp3a25), a testosterone 6β-hydroxylase. J Biochem Mol Toxicol 15:90-99.
7. Emoto C, Yamazaki H, Yamasaki S, Shimada N, Nakajima M, and Yokoi T (2000) Use of everted sacs of mouse small intestine as enzyme sources for the study of drug oxidation activities in vitro. Xenobiotica 30:971-982.
8. Gibaldi M and Perrier D (1982) Clearance concepts, in Pharmacokinetics, pp 319-351, Marcel Dekker, New York.
9. Herman RJ, Nakamura K, Wilkinson GR, and Wood AJ (1983) Induction of propranolol metabolism by rifampicin. Br J Clin Pharmacol 16:565-569.
10. Hickman D, Wang JP, Wang Y, and Unadkat JD (1998) Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 26:207-215.
11. Hogstedt S, Lindberg B, Peng DR, Regardh CG, and Rane A (1985) Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther 37:688-692.
12. Hogstedt S, Lindberg B, and Rane A (1983) Increased oral clearance of metoprolol in pregnancy. Eur J Clin Pharmacol 24:217-220.
13. Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, and Polli JW (2001) Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 29:754-760.
14. Itoh S, Satoh M, Abe Y, Hashimoto H, Yanagimoto T, and Kamataki T (1994) A novel form of mouse cytochrome P450 3A (Cyp3a-16): its cDNA cloning and expression in fetal liver. Eur J Biochem 226:877-882.
15. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Investig 101:289-294.
16. Kobayashi K, Urashima K, Shimada N, and Chiba K (2003) Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat. Drug Metab Dispos 31:833-836.
17. Kosel BW, Beckerman KP, Hayashi S, Homma M, and Aweeka FT (2003) Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 17:1195-1199.
18. Mankowski DC, Lawton MP, and Ekins S (2000) Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates. Xenobiotica 30:745-754.
19. Masuyama H, Hiramatsu Y, Mizutani Y, Inoshita H, and Kudo T (2001) The expression of pregnane X receptor and its target gene, cytochrome P450 3A1, in perinatal mouse. Mol Cell Endocrinol 172:47-56.
20. Mofenson LM (2003) Advances in the prevention of vertical transmission of human immunodeficiency virus. Semin Pediatr Infect Dis 14:295-308.
21. Nallani SC, Goodwin B, Maglich JM, Buckley DJ, Buckley AR, and Desai PB (2003) Induction of cytochrome P450 3A by paclitaxel in mice: pivotal role of the nuclear xenobiotic receptor, pregnane X receptor. Drug Metab Dispos 31:681-684.
22. Pang KS, Kong P, Terrell JA, and Billings RE (1985) Metabolism of acetaminophen and phenacetin by isolated rat hepatocytes: a system in which the spatial organization inherent in the liver is disrupted. Drug Metab Dispos 13:42-50.
23. Price JE, Barth RF, Johnson CW, and Staubus AE (1984) Injection of cells and monoclonal antibodies into mice: comparison of tail vein and retroorbital routes. Proc Soc Exp Biol Med 177:347-353.
24. Rey E, d'Athis P, Giraux P, de Lauture D, Turquais JM, Chavinie J, and Olive G (1979) Pharmacokinetics of clorazepate in pregnant and non-pregnant women. Eur J Clin Pharmacol 15:175-180.
25. Sachs B, Erdmann S, Al-Masaoudi T, and Merk HF (2001) In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. Br J Dermatol 144:316-320.
26. 1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 45:852-856.
27. Sakuma T, Endo Y, Mashino M, Kuroiwa M, Ohara A, Jarukamjorn K, and Nemoto N (2002) Regulation of the expression of two female-predominant CYP3A mRNAs (CYP3A41 and CYP3A44) in mouse liver by sex and growth hormones. Arch Biochem Biophys 404:234-242.
28. Sandoval TM, Grettenberger HM, Zhang KE, Hee BR, Lee CA, Shetty BV, Webber S, and Wu EY (1998) Metabolism of nelfinavir mesylate, an HIV-1 protease inhibitor, by human liver microsomes and recombinant human isoforms, in 12th Annual AAPS Meeting and Exposition; 1998 Nov 15-19; San Francisco, CA. Abstract 1096, American Association of Pharmaceutical Scientists, Arlington, VA.
29. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, and Schinkel AH (1999) Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Investig 104:1441-1447.
30. Thorne C and Newell ML (2004) Prevention of mother-to-child transmission of HIV infection. Curr Opin Infect Dis 17:247-252.
31. 3. Mol Pharmacol 60:1399-1406.
32. Towbin H, Staehelin T, and Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76:4350-4354.
33. Tracy TS, Venkataramanan R, Glover DD, and Caritis SN (2005) Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol 192:633-639.
34. Unadkat J and Wang Y (2000a) Antivirals, in Metabolic Drug Interactions (Levy RH, Thummel KE, Trager WF, Hansten PD, and Eichelbaum M eds) pp 421-433, Lippincott Williams & Wilkins, Philadelphia.
35. Unadkat JD and Wang Y (2000b) Antivirals, in Metabolic Drug Interactions (Levy RH, Thummel KE, Trager WF, Hansten PD, and Eichelbaum M eds) pp 647-652, Lippincott Williams & Wilkins, Philadelphia.
36. van Heeswijk RP, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, and Cameron DW (2004) The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 76:588-597.
37. Warrington JS, Poku JW, von Moltke LL, Shader RI, Harmatz JS, and Greenblatt DJ (2000) Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes. J Pharmacol Exp Ther 292:1024-1031.
38. Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, Kobayashi T, Maeda Y, Shetty B, and Webber S (2001) Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma and antiviral activities. Antimicrob Agents Chemother 45:1086-1093.